Allergan Inc AGN:NYSE (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
187.61 0.06   0.03%0.11%2,426,8662.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Latest News Headlines for Allergan Inc

Allergan Provides Update on Earnings Per Share -2-

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. Allergan has filed a solicitation/recommendation statement on Schedule 14D-9, as amended, with the SEC that has been mailed to Allergan's stockholders. In addition, Allergan has filed a preliminary proxy statement with the SEC on October 6, 2014 and intends to file a definitive proxy statement. Any definitive proxy statement will be mailed to Allergan's stockholders. INVESTORS AND STOCKHOLDERS OF ALLERGAN ARE ENCOURAGED TO READ THESE AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY MAY FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain free copies of these documents as they become available and any other documents filed with the SEC by Allergan at the SEC's website at www.sec.gov. In addition, copies will also be available at no charge at the Investors section of Allergan's website at www.allergan.com. Copies of these materials may also be requested from Allergan's information agent, Innisfree M&A; Incorporated, toll-free at 877-800-5187.

Allergan Provides Update on Earnings Per Share and Sales Expectations

IRVINE, Calif.--(BUSINESS WIRE)--October 09, 2014-- Allergan, Inc. (NYSE: AGN) today provided the following updates on earnings per share (EPS) and sales expectations based on current information.

Positive Study Results, Dividend, Regulatory Warning, Board Statements, and Technical Updates - Research Reports on Regeneron, CVS Health, Valeant, Allergan and Jazz

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 7, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), CVS Health Corporation (NYSE: CVS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Allergan Inc. (NYSE: AGN) and Jazz Pharmaceuticals plc (NASDAQ: JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6968-100free.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company's segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In April 2014, TauTona Group's subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.

http://www.allergan.com

Loading...

expand, down-facing arrow indicating expanded view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open187.56
Previous Close187.55
Day High189.929
Day Low186.18
52 Week High10/9/2014 | 192.98
52 Week Low11/7/2013 | 88.34
% Off 52 Week High-2.78%
% Off 52 Week Low112.37%
Beta (5 Yr)0.7
Volatility Avg10/10/2014 | 28.97
10-Day Avg. Volume2,948,693
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2014 | 4.37
P/E Ratio6/30/2014 | 43.0
Market CapLarge Cap | 55.8B
Shares Outstanding297.18M
Float296.6M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield0.11%
Ex-Date8/13/2014
Dividend Announcement7/21/2014
Date of Record8/15/2014
Payable$0.05 - QRTR
Payable Date9/5/2014

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.62M
Short Ratio3.2
Short % of Float1.22%
As of 9/15/2014

Peers Information HelpAGN Allergan Inc vs. Peers

Peers 
AGN
Allergan Inc
68.90%
Johnson & Johnson
10.53%
Pfizer Inc.
-4.90%
Merck & Co., Inc.
17.20%
Abbott Laboratories
8.37%
AGN
Allergan Inc
0.11%
Johnson & Johnson
2.77%
Pfizer Inc.
3.57%
Merck & Co., Inc.
3.00%
Abbott Laboratories
2.12%
AGN
Allergan Inc
0.03%
Johnson & Johnson
-0.83%
Pfizer Inc.
0.48%
Merck & Co., Inc.
-0.93%
Abbott Laboratories
0.31%
Compare these stocks